ReviewNature reviews. Endocrinology2026
Blood-based obesity biomarkers and their relevance for disease risk.
Review in Nature reviews. Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a risk factor for chronic diseases and early death; however, the underlying mechanisms are not fully understood. Whereas insulin resistance and inflammation are established pathways in several of these relationships, it is less clear how increases in body adipose tissue relate to these pathways and disease risk. Several adipose tissue-derived blood-based biomarkers have been identified as purported mediators, including adipokines, inflammatory cytokines and sex steroid hormones. Traditionally, these markers were discovered in animal models and their relevance in humans has then been investigated in epidemiological studies. Today, proteomics and metabolomics approaches in human observational studies are used to discover obesity biomarkers in blood, supported by Mendelian randomization studies to draw causal inferences. Here we review adipose tissue-derived blood-based obesity biomarkers and their relevance for disease risk, along with their potential role as mediators. Proteomics and metabolomics studies have partly re-identified traditional biomarkers, but more large-scale prospective analyses are needed to obtain evidence of the relevance of omics-based and traditional obesity biomarkers to disease.
Indexed as
Identifiers
41540119What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.